TY - JOUR
T1 - Recent trends and future directions for the medical treatment of ulcerative colitis
AU - Naganuma, Makoto
AU - Mizuno, Shinta
AU - Nanki, Kosaku
AU - Sugimoto, Shinya
AU - Kanai, Takanori
N1 - Publisher Copyright:
© 2016, Japanese Society of Gastroenterology.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) α treatments. Treatment options including calcineurin inhibitors and anti-TNF treatment for refractory UC are discussed in this article. Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib. Budesonide foamwill be used as one treatment option in patients with distal colitis. Herbal medicine, such as Qing-Dai is also effective for active UC and may be useful for patients who are refractory to anti-TNFα treatments. In the near future, physicians will able to use many different treatments for UC patients. However, we should not forget 5-ASA and corticosteroids as the fundamental treatments for UC patients.
AB - Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) α treatments. Treatment options including calcineurin inhibitors and anti-TNF treatment for refractory UC are discussed in this article. Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib. Budesonide foamwill be used as one treatment option in patients with distal colitis. Herbal medicine, such as Qing-Dai is also effective for active UC and may be useful for patients who are refractory to anti-TNFα treatments. In the near future, physicians will able to use many different treatments for UC patients. However, we should not forget 5-ASA and corticosteroids as the fundamental treatments for UC patients.
KW - Anti-TNF treatments
KW - Anti-adhesion antibody
KW - Calcineurin inhibitors
KW - The current treatment guideline for UC
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=84989950701&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989950701&partnerID=8YFLogxK
U2 - 10.1007/s12328-016-0686-z
DO - 10.1007/s12328-016-0686-z
M3 - Review article
C2 - 27699641
AN - SCOPUS:84989950701
SN - 1865-7257
VL - 9
SP - 329
EP - 336
JO - Clinical journal of gastroenterology
JF - Clinical journal of gastroenterology
IS - 6
ER -